Acelot — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Acelot is a private, preclinical-stage biotech applying a novel AI-driven drug discovery platform to historically intractable protein targets, starting with TDP-43 in ALS. The company's lead candidate, ACE-2223, is designed to inhibit and dissociate toxic TDP-43 aggregates, aiming to restore the protein's healthy function and address the root cause of the disease. With a team combining deep technical and entrepreneurial experience, Acelot is positioning itself as a pioneer in targeting TDP-43 pathology, a common driver across multiple neurodegenerative conditions. The company is actively presenting research and engaging with the scientific and investor community to advance its programs.

Neurodegenerative DiseasesAmyotrophic Lateral Sclerosis

Technology Platform

Integrated AI/ML and computational chemistry platform for de novo design of small molecules targeting complex, challenging protein structures and aggregation states.

Opportunities

Acelot's lead program targets the core TDP-43 pathology in ALS, a disease with no approved disease-modifying therapies, representing a high-value, unmet need.

Success in ALS could efficiently pave the way for expansion into larger neurodegenerative disease markets, including frontotemporal dementia and Alzheimer's disease, where TDP-43 pathology is also prevalent.

Risk Factors

The company faces high translational risk moving its novel TDP-43-targeting mechanism from preclinical models to human efficacy.

As a preclinical, private company, it is dependent on raising significant capital to fund expensive CNS clinical trials in a highly competitive funding and therapeutic landscape.

Competitive Landscape

The ALS competitive landscape includes companies targeting various pathways (SOD1, neuroinflammation, etc.), but direct inhibitors of TDP-43 aggregation are a nascent and highly specialized area, potentially giving Acelot a first-mover advantage. However, they will compete with larger biopharma entities and well-funded biotechs for patient recruitment, investor attention, and ultimately market share.

More companies in AI / Machine Learning →More companies in United States →